亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Abstract 6791: Target chronic inflammation in cancer and fibrosis with engineered immune cells

作者
Zeda Zhang,Yu-Jui Ho,Xin Fang,Marguerite Li,Min-Seo Kim,Clemens Hinterleitner,Sascha Haubner,Friederike Kogel,Edwin C. Pratt,Aveline A. Filliol,Michel Sadelain,Scott W. Lowe
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:86 (7_Supplement): 6791-6791
标识
DOI:10.1158/1538-7445.am2026-6791
摘要

Abstract Background: Chronic inflammatory disorders contribute to over 30% of global mortality and underlie major diseases such as cancer, fibrosis, and autoimmunity. Fibrosis is a hallmark of chronic inflammation following tissue injury that drives progressive organ dysfunction and cancer progression. Existing anti-fibrotic therapies are limited by modest efficacy and systemic toxicity. We hypothesize that the selective elimination of fibrogenic and inflammatory effector cells can disrupt self-perpetuating cycles of injury and inflammation, providing a targeted therapeutic avenue for chronic disease. Methods: Using proximity-based surface proteomics, we identified the urokinase plasminogen activator receptor (uPAR) as broadly upregulated in senescent and chronically injured tissues across cancer and fibrotic contexts. This was corroborated by a meta-analysis of eight senescence-focused and sixteen cancer transcriptomic datasets, as well as immunohistochemical validation on patient tissue microarrays. uPAR, a GPI-anchored membrane protein central to wound healing and tissue remodeling, is consistently elevated during chronic inflammation in cancer and fibrosis. In a somatic tissue-engineered syngeneic mouse model of ovarian cancer, we demonstrated the anti-tumor efficacy of murine uPAR-targeted CAR T cells. We then generated clinical-grade human uPAR-targeting single-chain variable fragments (scFvs) through phage display and hybridoma screening, and validated their ability to eradicate both orthotopic and metastatic xenograft tumors. Results: uPAR-targeted CAR T cells selectively eliminated senescent cells and attenuated fibrosis in preclinical models of liver and lung injury. In cancer, uPAR expression marks aggressive tumor cells undergoing epithelial-to-mesenchymal transition (EMT) and senescent stromal cells embedded in immunosuppressive niches. In multiple solid tumor models, including immune-excluded settings, human uPAR CAR T cells exhibited potent and durable anti-tumor activity. In an ovarian cancer model, adjuvant administration of uPAR CAR T cells post-surgical debulking effectively prevented metastatic recurrence. Therapeutic efficacy was tracked via noninvasive biomarkers, including circulating soluble uPAR and uPAR-targeted PET imaging. Despite detectable expression in subsets of myeloid cells, treatment with uPAR CAR T cells did not induce sustained myelodepletion in mice with a humanized immune system. Conclusions: These findings establish uPAR-targeted CAR T cells as a promising therapeutic strategy across cancer, fibrosis, and degenerative diseases by eliminating shared pathological cell states that sustain chronic inflammation and tissue dysfunction. Citation Format: Zeda Zhang, Yu-Jui Ho, Xin Fang, Marguerite Li, Minseo Kim, Clemens Hinterleitner, Sascha Haubner, Friederike Kogel, Edwin Pratt, Aveline FILLIOL, Michel Sadelain, Scott W. Lowe. Target chronic inflammation in cancer and fibrosis with engineered immune cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6791.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
香蕉乐曲完成签到,获得积分10
8秒前
32秒前
null的应助被科研通管家采纳,获得10
43秒前
沉静的愫完成签到,获得积分10
52秒前
1分钟前
ww完成签到,获得积分10
1分钟前
ww发布了新的文献求助10
1分钟前
1分钟前
adgn发布了新的文献求助10
1分钟前
老实的石头完成签到,获得积分10
1分钟前
2分钟前
个性鹭洋完成签到,获得积分10
2分钟前
丘比特的应助被adgn采纳,获得10
2分钟前
2分钟前
戴肉肉完成签到 ,获得积分10
2分钟前
深情安青的应助被科研通管家采纳,获得10
2分钟前
专注湘完成签到,获得积分10
2分钟前
范特西完成签到 ,获得积分10
3分钟前
忍冬完成签到,获得积分10
3分钟前
就吃一小口完成签到 ,获得积分10
3分钟前
AlexMoradi452发布了新的文献求助50
3分钟前
友好怜菡完成签到,获得积分10
3分钟前
跳跃的咖啡豆完成签到,获得积分10
3分钟前
3分钟前
4分钟前
盐水菠萝完成签到,获得积分10
4分钟前
rubbish发布了新的文献求助10
4分钟前
Wei发布了新的文献求助10
4分钟前
盐水菠萝发布了新的文献求助10
4分钟前
深情安青的应助被林楚棋采纳,获得10
4分钟前
陈淋完成签到,获得积分10
4分钟前
小巧的孤丹完成签到,获得积分10
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
大模型的应助被科研通管家采纳,获得10
4分钟前
4分钟前
所所的应助被科研通管家采纳,获得10
4分钟前
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
90min完成签到 ,获得积分10
4分钟前
科研通AI6.4的应助被盐水菠萝采纳,获得10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173069
求助须知:如何正确求助?哪些是违规求助? 9565519
关于积分的说明 21780335
捐赠科研通 7765068
什么是DOI,文献DOI怎么找? 3431528
关于科研通互助平台的介绍 2555609
邀请新用户注册赠送积分活动 2476668